Trial Parameters
Brief Summary
Clinical Outcomes and Safety of Sacituzumab Govitecan in Metastatic HER-2 negative Breast Cancer Patients
Eligibility Criteria
Inclusion Criteria: 1. Male or female aged 18 or above; 2. The Eastern Cooperative Oncology Group (ECOG) physical condition score of the United States is ≤2; 3. Unresectable or metastatic triple-negative breast cancer confirmed by tumor histology or cytology, and having received at least two systemic treatments previously (at least one of which was for metastatic disease); Or HR+/HER2- (IHC 0, 1+ or IHC 2+/ISH-) unresectable or metastatic breast cancer confirmed by tumor histology or cytology, with previous endocrine therapy and ≥2 lines of systemic therapy (for metastatic disease); 4. Receive gosatetuzumab treatment in the advanced stage; 5. During the study period, voluntarily abide by this trial protocol and receive regular follow-ups; 6. All women of childbearing age, fertile men or their spouses who have no plans for fertility or sperm donation throughout the trial period until 6 months after the last dose, or who voluntarily take effective contraceptive measures. Exclusion Criter